ARO7 Antibody

What is ARO7/AR-V7 Antibody and why is it important in cancer research?

ARO7/AR-V7 antibody is a specialized immunological reagent designed to detect the androgen receptor variant 7 (AR-V7), a truncated isoform of the androgen receptor that lacks the ligand-binding domain. The antibody recognizes the unique 16 amino acid C-terminal sequence (EKFRVGNCKHLKMTRP) of AR-V7, which is encoded by an alternate cryptic exon 3 .

This antibody is critically important in prostate cancer research as AR-V7 expression has been found to correlate with metastatic castration-resistant prostate cancer (CRPC) and primary resistance to therapies like abiraterone and enzalutamide . The ability to detect AR-V7 in circulating tumor cells (CTCs) provides a non-invasive diagnostic approach that may guide treatment decisions for CRPC patients .

Furthermore, AR-V7 protein detection offers insights beyond transcript-level analysis, including information about subcellular localization which may correlate with disease progression and therapy response . As Scher et al. reported, information regarding AR-V7 subcellular localization within CTCs adds important prognostic value related to disease progression and therapy response .

What are the available clones of ARO7/AR-V7 antibodies and how do they differ in performance?

Based on comprehensive comparative studies, at least seven commercially available AR-V7 antibodies exist with significant differences in specificity, sensitivity, and cross-reactivity profiles:

How should researchers validate the specificity of ARO7/AR-V7 antibodies?

A comprehensive validation strategy for ARO7/AR-V7 antibodies should include:

• Cell Line Panel Testing: Validate antibodies against cell lines with known AR/AR-V7 status:

  • Positive controls: 22RV1 (AR+/AR-V7+++) and VCaP (AR+++/AR-V7+)

  • Negative controls: LNCaP (AR+/AR-V7-), PC-3 (AR-/AR-V7-)

• Western Blot Validation:

  • Confirm detection of a specific band at ~80 kDa (AR-V7 size) in positive cell lines

  • Verify absence of bands at ~110-114 kDa (AR-FL size)

  • Assess cross-reactivity with other proteins in negative cell lines

• Immunocytochemistry/Immunohistochemistry Validation:

  • Confirm nuclear localization in AR-V7 positive cells

  • Evaluate signal-to-noise ratio and background staining

  • Test different fixation methods to optimize epitope preservation

• Transcript Correlation:

  • Validate AR-V7 protein expression against AR-V7 mRNA levels measured by techniques like droplet digital PCR (ddPCR)

• Epitope Analysis:

  • Ensure the antibody targets the unique 16 amino acid C-terminal sequence of AR-V7

  • Be aware that some antibodies contain antigen peptides with parts of the DNA binding domain (DBD) shared by AR-V7 and AR-FL, potentially affecting specificity

For optimal specificity, researchers should select antibodies that recognize the unique C-terminal domain without cross-reactivity to full-length AR or other proteins. The E308L clone has demonstrated superior performance in this regard, producing a clean signal in Western blotting and immunocytostaining with minimal background .

What is the relationship between ARO7/AR-V7 expression and prostate cancer progression?

The relationship between AR-V7 expression and prostate cancer progression is complex and clinically significant:

• Therapy Resistance: AR-V7 lacks the ligand-binding domain of the full-length androgen receptor, allowing it to remain constitutively active even in the absence of androgens. This enables continued androgen receptor signaling despite androgen deprivation therapy .

• Clinical Correlation: Detection of AR-V7 in circulating tumor cells has been associated with resistance to AR-targeting therapies and poorer clinical outcomes in CRPC patients .

• Early Expression: While initially thought to emerge primarily in CRPC, more recent research has demonstrated that nuclear AR-V7 expression can be detected in primary prostate cancer prior to long-term androgen deprivation and the development of castration resistance .

• Prognostic Value: In primary tumors, AR-V7 detection using certain antibodies (particularly AG10008) has been associated with shorter progression-free patient survival, suggesting prognostic value even before the development of castration resistance .

• Metastatic Correlation: AR-V7 expression has been found to correlate with metastatic CRPC, suggesting a role in disease dissemination .

Understanding this relationship is critical for developing treatment strategies and for patient stratification in clinical trials. The ability to detect AR-V7 in both tissue samples and CTCs provides valuable information for personalized treatment approaches in prostate cancer management.

How can researchers explain and address discrepancies in ARO7/AR-V7 detection between different antibody clones?

Discrepancies in AR-V7 detection between different antibody clones represent a significant challenge that researchers must address through methodological rigor. Several factors contribute to these inconsistencies:

To address these discrepancies, researchers should:

• Implement parallel validation using multiple antibodies on the same samples

• Include appropriate positive and negative controls for each experiment

• Correlate protein detection with mRNA expression

• Consider genetic knockdown of AR-V7 as a specificity control

• Explicitly report the antibody clone, detection methodology, and scoring criteria

• Interpret results within the context of the known limitations of the specific antibody used

This approach will help standardize AR-V7 detection and improve result reproducibility and clinical relevance across studies.

What methodological considerations are critical when using ARO7/AR-V7 antibodies in circulating tumor cell (CTC) analysis?

CTC analysis using ARO7/AR-V7 antibodies requires careful methodological consideration at each step:

• Sample Processing:

  • Process blood samples within 4 hours of collection to maintain CTC integrity

  • Use preservative tubes when immediate processing is not possible

• CTC Enrichment Strategy:

  • Negative depletion of leukocytes is preferable to positive selection methods that might interfere with antibody binding sites

  • Document recovery rates using spike-in experiments with cell lines of known AR-V7 status

• Antibody Selection:

  • The E308L clone has demonstrated superior performance for CTC detection with high signal-to-noise ratio and specific nuclear signal

  • This antibody detects CRPC CTCs more efficiently compared to previously used antibodies

• Optimization of Immunostaining Protocol:

  • Fixation: Test multiple fixation methods to preserve antigen structure

  • Blocking: Use stringent blocking to minimize background in rare cell detection

  • Antibody concentration: Titrate carefully to optimize signal-to-noise ratio

  • Incubation conditions: Standardize time and temperature

• Multi-marker Approach:

  • Combine AR-V7 staining with epithelial markers (cytokeratins, EpCAM) and leukocyte exclusion markers (CD45)

  • Consider adding proliferation markers (Ki-67) to assess functional status

• Subcellular Localization Assessment:

  • Evaluate nuclear versus cytoplasmic distribution of AR-V7

  • Nuclear localization may provide additional prognostic information

• Quantification and Reporting Standards:

  • Establish clear criteria for CTC identification and AR-V7 positivity

  • Report both the percentage of AR-V7 positive CTCs and staining intensity

  • Document subcellular localization patterns

These methodological considerations are critical for generating reproducible and clinically meaningful data when analyzing AR-V7 in the challenging context of rare circulating tumor cells.

How does subcellular localization of ARO7/AR-V7 correlate with functional activity and clinical outcomes?

The subcellular localization of AR-V7 provides important insights into its functional activity and clinical implications:

• Nuclear Localization and Transcriptional Activity:

  • AR-V7 functions primarily as a transcription factor, and its nuclear localization is associated with active signaling

  • Nuclear AR-V7 expression in primary prostate cancer tissues has been associated with shorter progression-free survival in studies using the AG10008 antibody

  • The E308L antibody demonstrates a specific nuclear signal in AR-V7 positive cells, consistent with its function as a transcription factor

• Diagnostic and Prognostic Value:

  • Information regarding AR-V7 subcellular localization within CTCs adds important prognostic information correlating to disease progression and therapy response

  • The presence of nuclear AR-V7 in primary tumors challenges the assumption that AR-V7 becomes relevant only after the development of castration resistance

• Methodological Requirements for Assessment:

  • High-quality nuclear counterstaining is essential for accurate localization assessment

  • Clear distinction between nuclear and cytoplasmic signals requires optimal fixation and staining protocols

  • The E308L antibody provides superior signal-to-noise ratio for accurate subcellular localization determination

• Quantitative Approaches:

  • Nuclear-to-cytoplasmic ratio quantification may provide more objective assessment

  • Digital image analysis with nuclear segmentation improves reproducibility of localization assessment

• Clinical Correlation:

  • Studies have suggested that the subcellular distribution of AR-V7 may change in response to therapy

  • The dynamic changes in localization could potentially serve as a biomarker of treatment response or resistance development

For accurate assessment of AR-V7 subcellular localization, researchers should employ antibodies with demonstrated nuclear specificity like E308L, utilize proper nuclear counterstaining, and adopt standardized criteria for classification of localization patterns to ensure reproducibility across studies .

What strategies can overcome the challenges in distinguishing ARO7/AR-V7 from full-length AR in experimental settings?

Distinguishing AR-V7 from full-length androgen receptor (AR-FL) in experimental settings requires strategic approaches to overcome several technical challenges:

• Antibody Selection and Validation:

  • Use antibodies specifically validated against the unique 16 amino acid C-terminal sequence of AR-V7

  • The E308L clone has demonstrated superior specificity with minimal cross-reactivity to AR-FL

  • Avoid antibodies generated using antigens containing portions of the DNA binding domain (DBD) shared with AR-FL

• Western Blot Optimization:

  • Use gradient gels (4-12%) for better separation of AR-V7 (~80 kDa) from AR-FL (~110-114 kDa)

  • Run positive controls (22RV1 cells) alongside samples to establish correct band sizes

  • Probe parallel blots with N-terminal AR antibodies to detect both forms for comparison

• Immunohistochemistry/Immunocytochemistry Approaches:

  • Implement dual staining with C-terminal AR-FL specific antibodies and AR-V7 specific antibodies

  • Use spectral imaging to distinguish different fluorophores when signals overlap spatially

  • Apply standardized scoring criteria that account for staining intensity and subcellular localization

• Molecular Validation:

  • Correlate protein detection with AR-V7 mRNA expression using techniques like droplet digital PCR

  • Consider RNA-based techniques like in situ hybridization to detect AR-V7-specific transcripts

• Genetic Manipulation Controls:

  • Use AR-V7 knockdown in positive cell lines (e.g., 22RV1) to validate antibody specificity

  • Consider AR-V7 overexpression models in AR-V7 negative cell lines as positive controls

• Functional Discrimination:

  • Assess response to anti-androgens in experimental models, as AR-V7 activity is ligand-independent

  • Evaluate AR-V7-specific transcriptional targets to functionally distinguish from AR-FL activity

By implementing these strategies, researchers can more confidently distinguish AR-V7 from AR-FL, leading to more reliable experimental results and potentially more accurate clinical correlations in prostate cancer research.

What is the optimal protocol for detecting ARO7/AR-V7 in Western blot applications?

The following optimized protocol for AR-V7 detection in Western blot applications addresses the specific challenges associated with this protein:

Sample Preparation:

• Lyse cells in RIPA buffer supplemented with protease inhibitors

• Include phosphatase inhibitors to preserve post-translational modifications

• Sonicate briefly to shear DNA and reduce sample viscosity

• Determine protein concentration using BCA or Bradford assay

Gel Electrophoresis:

• Load 30-50 μg of total protein per lane

• Use 4-12% gradient gels for optimal separation of AR-V7 (~80 kDa) from AR-FL (~110-114 kDa)

• Include positive controls: 22RV1 cell lysate (AR+/AR-V7+++) and VCaP cell lysate (AR+++/AR-V7+)

• Include negative controls: LNCaP cell lysate (AR+/AR-V7-) and PC-3 cell lysate (AR-/AR-V7-)

• Run at 100V until adequate separation is achieved

Transfer:

• Use wet transfer for optimal transfer of high molecular weight proteins

• Transfer at 30V overnight at 4°C to ensure complete transfer

• Verify transfer efficiency with Ponceau S staining

Immunodetection:

• Block membranes in 5% non-fat dry milk in TBST for 1 hour at room temperature

• Incubate with anti-AR-V7 antibody (E308L clone recommended) at 1:1000 dilution in 5% BSA/TBST overnight at 4°C

• Wash 3 times with TBST, 5 minutes each

• Incubate with HRP-conjugated secondary antibody at 1:5000 dilution for 1 hour at room temperature

• Wash 3 times with TBST, 5 minutes each

• Develop using enhanced chemiluminescence (ECL) reagent

• Capture images with appropriate exposure to avoid saturation

Validation and Controls:

• Strip and reprobe with an N-terminal AR antibody to detect both AR-FL and AR-V7

• Include β-actin or GAPDH as loading controls

• For confirmation, consider running a parallel blot with a second validated AR-V7 antibody (e.g., RM7)

Result Interpretation:

• AR-V7 should appear as a distinct band at approximately 80 kDa in positive control cell lines

• Confirm absence of signal at this position in negative control cell lines

• Evaluate for non-specific bands, which should be minimal with the E308L antibody

• Document full blot images including molecular weight markers

This protocol consistently produces specific detection of AR-V7 with minimal cross-reactivity, facilitating reliable assessment in research samples.

How should researchers design control experiments when using ARO7/AR-V7 antibodies in immunohistochemistry?

Designing comprehensive control experiments is essential for reliable immunohistochemistry (IHC) with AR-V7 antibodies. The following control strategy addresses the specific challenges of AR-V7 detection:

1. Tissue/Cell Line Controls:

• Positive Tissue Controls:

  • CRPC tissues with known AR-V7 expression

  • Primary prostate cancer tissues with verified AR-V7 status

  • Include tissues with variable expression levels to establish detection thresholds

• Cell Line Controls:

  • Prepare formalin-fixed, paraffin-embedded cell blocks of:

    • 22RV1 cells (high AR-V7 expression)

    • VCaP cells (moderate AR-V7 expression)

    • LNCaP cells (AR-V7 negative control)

    • PC-3 cells (AR and AR-V7 negative control)

  • Process these controls alongside clinical samples to ensure consistent fixation and processing

2. Technical Controls:

• Antibody Controls:

  • Primary antibody omission to assess non-specific binding of secondary antibody

  • Isotype control at the same concentration as the primary antibody

  • Peptide competition assay using the specific AR-V7 C-terminal peptide to confirm specificity

• Multiple Antibody Validation:

  • Run parallel sections with two validated AR-V7 antibodies (e.g., E308L and AG10008)

  • Compare staining patterns to identify potential discrepancies

3. Protocol Validation Controls:

• Antigen Retrieval Assessment:

  • Test multiple antigen retrieval methods on control tissues

  • Document optimal conditions for specific epitope exposure

• Antibody Titration:

  • Test serial dilutions to determine optimal antibody concentration

  • Balance specific signal versus background

4. Analytical Controls:

• Blinded Scoring:

  • Have two independent pathologists score slides without knowledge of clinical data

  • Establish inter-observer agreement statistics

• Quantification Controls:

  • Use digital image analysis for reproducible quantification

  • Include calibration slides to standardize intensity measurements across batches

5. Specificity Validation:

• RNA-Protein Correlation:

  • When possible, correlate IHC results with AR-V7 mRNA expression in the same samples

  • Consider RNA in situ hybridization on sequential sections for direct comparison

• Subcellular Localization Assessment:

  • Document nuclear versus cytoplasmic staining patterns

  • Compare with known functional localization of AR-V7

By implementing this comprehensive control strategy, researchers can significantly improve the reliability and interpretability of AR-V7 immunohistochemistry, addressing the known issues of antibody variability and staining pattern discrepancies .

What are the best practices for using ARO7/AR-V7 antibodies in multiplex immunofluorescence studies?

Multiplex immunofluorescence (IF) with AR-V7 antibodies enables simultaneous analysis of multiple biomarkers in the same sample. The following best practices ensure optimal results:

Antibody Selection and Panel Design:

• AR-V7 Antibody Selection:

  • Choose the E308L clone for its superior signal-to-noise ratio and specific nuclear signal

  • Verify compatibility with multiplex protocols through single-marker validation first

• Panel Design Considerations:

  • Core markers to include with AR-V7:

    • Full-length AR (using N-terminal targeting antibody)

    • Epithelial markers (cytokeratins, EpCAM)

    • Proliferation markers (Ki-67)

    • Prostate-specific markers (PSA, PSMA)

  • Select primary antibodies from different host species when possible

  • Consider directly conjugated primary antibodies to avoid species cross-reactivity

Protocol Optimization:

• Sequential Staining Protocol:

  • Antigen retrieval: Optimize pH and buffer composition for all targets

  • Blocking: 10% normal serum + 1% BSA (1 hour at room temperature)

  • Primary and secondary antibody incubation: Optimize times and temperatures

  • Include stringent washing steps between antibodies

  • Nuclear counterstain: DAPI (1 μg/mL)

• Tyramide Signal Amplification (TSA) Approach:

  • For same-species antibodies, implement TSA with antibody stripping:

    • Apply primary antibody

    • Apply HRP-conjugated secondary antibody

    • Develop with tyramide-fluorophore

    • Microwave to strip antibodies but preserve fluorophore signal

    • Repeat sequence for additional markers

Quality Control Measures:

• Controls for Multiplex Validation:

  • Single-stained controls for spectral unmixing

  • Fluorophore minus one (FMO) controls to assess bleed-through

  • Isotype controls for each primary antibody

  • Cell line controls with known AR-V7 status (22RV1, VCaP, LNCaP)

• Order of Antibody Application:

  • Test different antibody sequences to determine optimal staining order

  • Generally apply the AR-V7 antibody early in the sequence for optimal epitope access

Image Acquisition and Analysis:

• Multispectral Imaging:

  • Use systems capable of spectral unmixing (e.g., Vectra, Mantra)

  • Capture at 20-40x magnification for subcellular detail

• Analysis Approach:

  • Implement cell segmentation algorithms for single-cell analysis

  • Quantify marker co-expression and mutual exclusivity

  • Analyze nuclear/cytoplasmic ratio of AR-V7

  • Correlate AR-V7 patterns with other markers

Data Reporting and Validation:

• Standardized Reporting:

  • Document complete antibody information, including clone, vendor, and dilution

  • Report both percentage positivity and intensity metrics

  • Include representative images showing co-localization patterns

• Clinical Correlation:

  • Correlate multiplex findings with clinical outcomes

  • Identify potentially meaningful biomarker combinations

By following these best practices, researchers can generate high-quality multiplex immunofluorescence data that reveals the complex relationships between AR-V7 and other biomarkers in the prostate cancer microenvironment, potentially advancing our understanding of resistance mechanisms and treatment response.

How should researchers interpret conflicting ARO7/AR-V7 antibody data in publication and experimental results?

Understanding Sources of Discrepancy:

• Antibody-Related Factors:

  • Different epitope recognition: Some antibodies target only the unique C-terminus, while others include portions of the DNA binding domain shared with full-length AR

  • Varying specificity profiles: Significant differences exist in cross-reactivity patterns among antibodies, with some detecting smaller non-AR-V7 proteins

  • Batch-to-batch variability: Commercial antibodies may show inconsistencies between lots

• Methodological Differences:

  • Detection techniques vary widely (Western blot, IHC, IF) with different fixation protocols

  • Antigen retrieval methods affect epitope accessibility

  • Scoring criteria and thresholds for positivity differ between studies

Critical Analysis Framework:

Reconciliation Strategies:

• Comparative Analysis:

  • When reviewing publications, construct a comparison table of:

    • Antibody clone and manufacturer

    • Detection method and protocol details

    • Validation approaches

    • Key findings and clinical correlations

• Weighting Evidence:

  • Give greater weight to studies using extensively validated antibodies (e.g., E308L)

  • Consider the biological plausibility of findings in the context of AR biology

  • Prioritize studies with functional correlations over purely descriptive findings

• Replication Approaches:

  • When designing experiments, use multiple validated antibodies in parallel

  • Complement protein detection with mRNA analysis

  • Consider functional assays to validate the biological relevance of findings

Practical Recommendations:

• For Research Design:

  • Select antibodies based on the specific application (E308L for CTCs; AG10008 for primary tumor prognostic studies)

  • Include comprehensive controls

  • Complement antibody studies with RNA detection methods

• For Data Interpretation:

  • Consider antibody limitations when interpreting results

  • Report findings in the context of the specific antibody used

  • Acknowledge potential discrepancies with other antibodies

• For Publication Review:

  • Critically evaluate antibody validation methods

  • Consider whether conflicting results may reflect detection of different AR-V7 pools or modifications

  • Look for convergent evidence from multiple methodologies

By applying this systematic approach to conflicting AR-V7 antibody data, researchers can better interpret the literature, design more robust experiments, and advance understanding of AR-V7 biology in prostate cancer research .